Earnings Call · Q2 FY2024·2024-08-09

Q2 24EPS -33.33%·Rev n/aQ1 24EPS +100.00%*·Rev n/aQ4 23EPS +100.00%*·Rev n/aQ3 23EPS +100.00%*·Rev n/a⚠ consensus missing

CytomX Therapeutics, Inc. CTMX

Chris Ogden — Chief Financial Officer

Sean McCarthy — Chairman and CEO

+1.7%1d on move date+1.3% vs SPY3d−1.7%5d+0.8%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more CTMX calls or request research access.

More CTMX calls Browse calls Request research access